Research
Hormonal
Tirzepatide (5, 10, 15 mg weekly) produces substantial, dose-dependent weight loss in patients with obesity or overweight with comorbidities, outperforming placebo.
Tirzepatide is a dual GIP/GLP-1 agonist that produces significant, dose-dependent weight loss (up to 17.8% at 15 mg weekly). It is administered subcutaneously once weekly. As of September 2023, it was not approved for obesity treatment in Switzerland, so availability may be limited.
StrongSupportsHIGH confidence
Nach 72-wöchiger Therapie konnte das Gewicht in der Tirzepatid-Gruppe placebokorrigiert um durchschnittlich 11,9 % (Dosis: 5 mg), 16,4 % (Dosis: 10 mg) bzw. 17,8 % (Dosis: 15 mg) reduziert werden.
Why this rating
Based on the SURMOUNT-1 Phase III trial cited.
Source
Neue Behandlungsmöglichkeiten der Adipositas
Ellen Heitlinger et al. · 2024
DOI 10.36000/hbt.2023.11.001
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (Liraglutide, Semaglutide) and dual GIP/GLP-1 agonists (Tirzepatide) produce significant, sustained weight loss in adults with obesity or overweight with comorbidities, outperforming placebo.Strong
- Semaglutide (2.4 mg weekly) produces greater weight loss than Liraglutide (3.0 mg daily) in patients with obesity or overweight with comorbidities.Strong
- Bariatric surgery is the most effective, sustainable, and generally safe therapy for severe obesity (BMI ≥ 35 kg/m²) when lifestyle and pharmacological treatments have failed.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →